CytoDyn (CytoDyn) EBIT per Share : $-0.05 (TTM As of Feb. 2024)

View and export this data going back to 2005. Start your Free Trial

What is CytoDyn EBIT per Share?

CytoDyn's EBIT per Share for the three months ended in Feb. 2024 was $-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.05.

During the past 3 years, the average EBIT per Share Growth Rate was 34.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 21.40% per year. During the past 10 years, the average EBIT per Share Growth Rate was 9.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for CytoDyn's EBIT per Share or its related term are showing as below:

CYDY' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -60.7 Med: 2.6 Max: 34.8
Current: 34.8

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of CytoDyn was 34.80% per year. The lowest was -60.70% per year. And the median was 2.60% per year.

CYDY's 3-Year EBIT Growth Rate is ranked better than
84.52% of 1311 companies
in the Biotechnology industry
Industry Median: 3.5 vs CYDY: 34.80

CytoDyn's EBIT for the three months ended in Feb. 2024 was $-10.36 Mil.

CytoDyn EBIT per Share Historical Data

The historical data trend for CytoDyn's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn EBIT per Share Chart

CytoDyn Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

EBIT per Share

Get a 7-Day Free Trial

-0.21

-0.26

-0.20

-0.29

-0.09

CytoDyn Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
EBIT per Share	Get a 7-Day Free Trial															-0.01	-0.02	-0.01	-0.01	-0.01

CytoDyn EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

CytoDyn's EBIT per Share for the fiscal year that ended in May. 2023 is calculated as

	EBIT per Share		(A: May. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-73.074	/	836.528
=	-0.09

CytoDyn's EBIT per Share for the quarter that ended in Feb. 2024 is calculated as

	EBIT per Share		(Q: Feb. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-10.36	/	982.209
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05

CytoDyn (OTCPK:CYDY) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

CytoDyn EBIT per Share Related Terms

Thank you for viewing the detailed overview of CytoDyn's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoDyn (CytoDyn) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

296:Germany

Address

1111 Main Street, Suite 660, Vancouver, WA, USA, 98660

Website

https://www.cytodyn.com

CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

Executives

Tyler Blok	officer: EVP of Legal Affairs	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes	director
Ryan Dunlap	director	310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman	officer: President	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins	director	1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese	officer: Chief Financial Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor	officer: Chief Operating Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland	officer: CFO, Treasurer and Secretary	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660